BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chai R, Xue W, Shi S, Zhou Y, Du Y, Li Y, Song Q, Wu H, Hu Y. Cardiac Remodeling in Heart Failure: Role of Pyroptosis and Its Therapeutic Implications. Front Cardiovasc Med 2022;9:870924. [DOI: 10.3389/fcvm.2022.870924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun Z, Fang C, Xu S, Wang B, Li D, Liu X, Mi Y, Guo H, Jiang J. SIRT3 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Activation of the NLRP3 Inflammasome via Autophagy. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.115354] [Reference Citation Analysis]
2 Shi Y, Zhao L, Wang J, Liu S, Zhang Y, Qin Q. The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175364] [Reference Citation Analysis]
3 Horvath C, Kararigas G. Sex-dependent mechanisms of cell death modalities in cardiovascular disease. Can J Cardiol 2022:S0828-282X(22)00864-9. [PMID: 36152770 DOI: 10.1016/j.cjca.2022.09.015] [Reference Citation Analysis]
4 Habimana O, Modupe Salami O, Peng J, Yi GH. Therapeutic Implications of Targeting Pyroptosis in Cardiac-related Etiology of Heart Failure. Biochem Pharmacol 2022;:115235. [PMID: 36044938 DOI: 10.1016/j.bcp.2022.115235] [Reference Citation Analysis]
5 Yanpiset P, Maneechote C, Sriwichaiin S, Siri-angkul N, Chattipakorn SC, Chattipakorn N. Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: Cumulative evidence for future cardioprotective strategies. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.007] [Reference Citation Analysis]